Augustine Therapeutics is a Belgian biotech company focused on developing innovative treatments for neurodegenerative and cardio-metabolic diseases. It specializes in HDAC6 inhibitors, a class of drugs that target cellular processes involved in nerve and muscle function. The company was founded on research from Professor Ludo Van Den Bosch at the VIB-KU Leuven Center for Brain and Disease Research. Its lead drug candidate, AGT-100216, is aimed at treating Charcot-Marie-Tooth (CMT) disease. Backed by major investors like Novo Holdings and Jeito Capital, Augustine is expanding its research and clinical trials, aiming to create safer and more effective treatments for chronic diseases.